Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 18/20 | 0.82 |
| ▸ | SSTR3 | P32745 | 15/20 | 0.82 |
| ▸ | SSTR2 | P30874 | 12/20 | 0.82 |
| ▸ | SSTR5 | P35346 | 12/20 | 0.82 |
| ▸ | SSTR1 | P30872 | 5/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29938085 | 1.00 | SSTR4 (0.82) | SSTR4SSTR3SSTR2SSTR5SSTR1 | |
| SCHEMBL29938282 | 1.00 | SSTR4 (0.82) | SSTR4SSTR3SSTR2SSTR5SSTR1 | |
| SCHEMBL29938207 | 1.00 | SSTR4 (0.82) | SSTR4SSTR3SSTR2SSTR5SSTR1 | |
| SCHEMBL29938227 | 0.98 | SSTR1 (0.79) | SSTR4SSTR3SSTR2SSTR5SSTR1 | |
| SCHEMBL14454053 | 0.97 | SSTR4 (0.87) | SSTR4SSTR3SSTR2SSTR5SSTR1 | |
| SCHEMBL29937692 | 0.97 | SSTR4 (0.87) | SSTR4SSTR3SSTR2SSTR5SSTR1 | |
| SCHEMBL29938213 | 0.97 | SSTR4 (0.87) | SSTR4SSTR3SSTR2SSTR5SSTR1 | |
| SCHEMBL29938074 | 0.97 | SSTR4 (0.87) | SSTR4SSTR3SSTR2SSTR5SSTR1 | |
| SCHEMBL29937664 | 0.97 | SSTR4 (0.87) | SSTR4SSTR3SSTR2SSTR5SSTR1 | |
| SCHEMBL29938171 | 0.97 | SSTR4 (0.87) | SSTR4SSTR3SSTR2SSTR5SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064996-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. | 2025-02-27 | — | — | US | disclosed |
| US-11819556-B2 | Stabilized compositions of radionuclides and uses thereof | RAYZEBIO, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11707540-B2 | Stabilized compositions of radionuclides and uses thereof | RAYZEBIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230144360-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11541134-B1 | Stabilized compositions of radionuclides and uses thereof | RAYZEBIO, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11497822-B1 | Stabilized compositions of radionuclides and uses thereof | RAYZEBIO, INC. (US) | 2022-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11497822-B1 | Stabilized compositions of radionuclides and uses thereof | TFRC, SLC39A14, EGFR | SSTR4 71/4885SSTR3 137/4885SSTR2 167/4885 |
| US-11819556-B2 | Stabilized compositions of radionuclides and uses thereof | TFRC, SLC39A14, EGFR | SSTR4 71/4885SSTR3 137/4885SSTR2 167/4885 |
| US-20250064996-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | TFRC, SLC39A14, EGFR | SSTR4 71/4885SSTR3 137/4885SSTR2 167/4885 |
| US-11541134-B1 | Stabilized compositions of radionuclides and uses thereof | TFRC, SLC39A14, EGFR | SSTR4 71/4885SSTR3 137/4885SSTR2 167/4885 |
| US-20230144360-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | TFRC, SLC39A14, EGFR | SSTR4 71/4885SSTR3 137/4885SSTR2 167/4885 |
| US-11707540-B2 | Stabilized compositions of radionuclides and uses thereof | TFRC, SLC39A14, EGFR | SSTR4 71/4885SSTR3 137/4885SSTR2 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.